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Cannabigerol (CBG) is one of the major phytocannabinoids present in Cannabis sativa
L. that is attracting pharmacological interest because it is non-psychotropic and is
abundant in some industrial hemp varieties. The aim of this work was to investigate
in parallel the binding properties of CBG to cannabinoid CB1 (CB1R) and CB2 (CB2R)
receptors and the effects of the compound on agonist activation of those receptors and
of CB1–CB2 heteroreceptor complexes. Using [3H]-CP-55940, CBG competed with
low micromolar K i values the binding to CB1R and CB2R. Homogeneous binding in
living cells, which is only technically possible for the CB2R, provided a 152 nM K i value.
Also interesting, CBG competed the binding of [3H]-WIN-55,212-2 to CB2R but not to
CB1R (K i: 2.7 versus >30 µM). The phytocannabinoid modulated signaling mediated
by receptors and receptor heteromers even at low concentrations of 0.1–1 µM. cAMP,
pERK, β-arrestin recruitment and label-free assays in HEK-293T cells expressing the
receptors and treated with endocannabinoids or selective agonists proved that CBG is
a partial agonist of CB2R. The action on cells expressing heteromers was similar to that
obtained in cells expressing the CB2R. The effect of CBG on CB1R was measurable but
the underlying molecular mechanisms remain uncertain. The results indicate that CBG
is indeed effective as regulator of endocannabinoid signaling.
Keywords: cannabinoid receptor, cannabigerol, G-protein-coupled receptor, phytocannabinoid, TR-FRET, partial
agonist
Abbreviations: 18-THC, 18-tetrahydrocannabinol; 19-THC, 19-tetrahydrocannabinol; 19-THCA, 19- tetrahy
drocannabinolic acid; 19-THCV, 19-tetrahydrocannabivarin; 2-AG, 2-arachidonoyl glicerol; AEA, anandamide; CB1R,
cannabinoid receptor 1; CB2R, cannabinoid receptor 2; CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiolic
acid; CBDV, cannabidivarin; CBG, cannabigerol; CBGA, cannabigerolic acid; CBN, cannabinol; CNS, central nervous system;
DMR, dynamic mass redistribution; HEK, human embryonic kidney; HTRF, homogeneous time-resolved fluorescence;
SNAP, protein used as a tag; it contains circa 180 amino acids and may be covalently labeled with different probes; Tb,
terbium; TLB, Tag-lite labeling medium.
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INTRODUCTION
Cannabinoid compounds bind and activate cannabinoid
CB1 (CB1R) and CB2 (CB2R) receptors, which belong to the
superfamily of G-protein-coupled receptors. There are many
ways to classify them, but the most used distinguishes between
endogenous molecules (endocannabinoids), phytocannabinoids
and synthetic cannabinoids. Endocannabinoids and one of the
most studied phytocannabinoids, 19-tetrahydrocannabinol
(19-THC), are agonists with more or less CB1R/CB2R
selectivity. Furthermore, synthetic cannabinoids mainly act
(as agonists or antagonists) by binding to the orthosteric site
of receptors (Mechoulam, 2016). Indeed, there is a limited
number of molecules, either synthetic or phytocannabinoids,
that behave as allosteric modulators of cannabinoid receptor
function.
Anandamide and 2-arachidonoyl glycerol (2-AG) are the
two main endocannabinoids, being synthesized from membrane
lipids and having an alkyl-amide chemical structure. They are
retrograde effectors being produced in the post-synaptic neuron
to act in the pre-synaptic neuron where they regulate the release
of neurotransmitters (Diana and Marty, 2004).
Phytocannabinoids are phenolic terpenes biosynthesized
in nature nearly exclusively in the Cannabis sativa L. plant.
In the Cannabis plant, all cannabinoids are biosynthesized in
the acid form, mainly 19-THCA, CBDA, etc. CBGA is the
first molecule formed in the biosynthetic pathway and the
substrate of 19-tetrahydrocannabinol-synthase and CBD-
synthase (Fellermeier and Zenk, 1998). The pharmacologic
effects of Cannabis components, traditionally consumed
through inhalation, are attributed to the decarboxylated neutral
products of above mentioned acids: 19-THC, CBD, and
CBG.
Synthetic cannabinoids are very different in chemical
structure. For instance, they may be indoles like WIN-55,212-
2, AM-1241 or JWH-018, or phenolic, phenols lacking the
pyrene ring, like CP-55,940 or HU-308. All these compounds
have been used in cannabinoid research and have helped to
unveil pharmacological aspects of the endocannabinoid system.
It should be noted that some of these compounds have
recently arrived at the streets sold as legal highs, thus raising
Public Health concerns (Adams et al., 2017; Weinstein et al.,
2017).
The endocannabinoid system is constituted by the
endogenous cannabinoids, the enzymes that produce and
degrade them, and by the receptors that mediate their
actions. Whereas endocannabinoids consist of molecules
with aliphatic structure, AEA and 2-AG, the structure of
natural cannabinoids, derived from C. sativa L., is fairly
different [see (Lu and Mackie, 2016) and references therein].
Although it is well established that one of the main active
components of the plant and one of the few that are psychoactive,
namely 19-THC, acts via cannabinoid receptors, there is
controversy on whether these receptors mediate the action of
phytocannabinoids such as CBN, CBD or CBG. As happened
the last years for CBD, a new research and revision of the
cannabinoid receptor pharmacology must be done with the
rest of phytocannabinoids as CBG. A further phenomenon that
may be considered to understand the action of molecules from
C. sativa L. and its extracts is the fact that cannabinoid receptors
may form heteromers, namely CB1–CB2 heteroreceptors,
which display particular functional properties (Callén et al.,
2012). It should be noted that in CNS those heteromers are
mainly expressed in pallidal neurons (Lanciego et al., 2011;
Sierra et al., 2015) and in activated microglia (Navarro et al.,
2018a).
Cannabigerol was isolated, characterized and synthetized
by the same researchers than reported the structure of the
main psychotropic agent of Cannabis, 19-THC (Gaoni and
Mechoulan, 1964). Few years later in vivo assays showed
that CBG was non-psychoactive (Grunfeld and Edery, 1969;
Mechoulam et al., 1970). The lower concentration and the lack
of psychoactivity was probably the cause that CBG was shadowed
by 19-THC. In fact, CBG has attracted less attention than 19-
THC and even than CBD, but nowadays is gaining interest among
the scientific community. Some commercial hemp varieties have
CBG and CBGA as main cannabinoids and, therefore, CBG
is another of the phytocannabinoids to be considered by the
unregulated market of hemp oils and derivatives. As recently
pointed out, the increased therapeutic potential of C. sativa
L. components requires a more in deep understanding of
the pharmacology of phytocannabinoids other than 19-THC,
namely CBD, CBG, CBN, 19-THCV, 18-THC, CBC and CBDV
(Turner et al., 2017).
Preliminary results using membranes from mice brain or
from CHO cells expressing the human CB2R led to postulate
that CBG could be a partial agonist at both CB1R and CB2R
with K i values in the 300–500 nM range (Gauson et al., 2007;
Pertwee, 2008). The first published data on the binding of
CBG to human CB1R and CB2R were provided by (Rosenthaler
et al., 2014) working with [3H]CP-55,940 as radioligand and
with preparations from Sf9 cells co-expressing one receptor and
the Gαi3β1γ2 protein. The K i values obtained in competition
assays are 897 and 153 nM for CB1R and CB2R, respectively.
CBG may modulate the activity of transient receptor potential
channels of ankyrin type-1; however, the EC50 values lie in
the micromolar range (De Petrocellis et al., 2008). It has been
reported that CBG binds to CB1R (K i = 381 nM) from mouse
brain membranes and CB2R (K i = 2.6 µM) from CHO cells
expressing the human receptor; CBG at high concentrations
(10 µM) antagonized [35S]GTPγS binding in mouse brain
membranes treated with AEA or CP-55940 (Cascio et al.,
2010). Authors also reported CBG as α2-adrenoceptor agonist
at nanomolar levels (EC50 = 0.2 nM), and being also able to
antagonize [35S]GTPγS binding upon stimulation of the 5HT1A
receptor by 1 µM 8-OH-DPAT (Cascio et al., 2010). Other
findings indicate that CBG can act as (i) agonist/desensitizer of
TRPA1 (EC50 = 700 nM), (ii) agonist of TRPV1 (EC50 = 1.3 µM)
(iii) agonist of TRPV2 (EC50 = 1.7 µM), (iv) antagonist of TRPM8
channels (IC50 = 160 nM) and v) inhibitor of AEA cell uptake
(K i = 11.3 µM) (De Petrocellis et al., 2011). More recently, the
PPARγ has been reported as target of the phytocannabinoid CBG
(K i = 11.7 µM) that at high concentrations, in the 10–25 µM
range, may enhance the PPARγ transcriptional activity (Granja
Frontiers in Pharmacology | www.frontiersin.org 2 June 2018 | Volume 9 | Article 632
fphar-09-00632 June 19, 2018 Time: 19:17 # 3
Navarro et al. Cannabigerol Action at Cannabinoid Receptors
et al., 2012; Nadal et al., 2017). A recent review substantiates the
complexity of the field and highlights that other players, GPR55
for instance, are also targeted by cannabinoids (Solymosi and
Kofalvi, 2017).
The aim of this work was to characterize CBG pharmacology
on the cannabinoid receptors using binding and measurement
of different signal transduction mechanisms in living HEK-293T
cells expressing human CB1R, CB2R, or CB1–CB2 heteroreceptor
complexes. The results indicate that, in our experimental




ACEA, JWH133, and AEA were purchased from Tocris
Bioscience (Bristol, United Kingdom), CBD and CBG analytical
standard solutions were purchased from THCpharm (Frankfurt,
DE). Concentrated (10 mM) stock solutions prepared in ethanol
(CBG, ACEA, and AEA) or DMSO (JWH133 and CM-157)
were stored at −20◦C. In each experimental session, aliquots
of concentrated solutions of compounds were thawed and
conveniently diluted in the appropriate experimental solution.
For non-radioactive binding assays, TLB was obtained from
Cisbio Bioassays (LABMED; Codolet, France). The Tb derivative
of O6-benzylguanine was synthesized by Cisbio Bioassays
and is commercialized as SNAP-Lumi4-Tb (SSNPTBC; Cisbio
Assays). The plasmid encoding for the SNAP-tagged human
CB2R used for transient transfection was obtained from Cisbio
Bioassays (PSNAP-CB2). CB2R agonist 3-[[4-[2-tert-butyl-
1-(tetrahydropyran-4-ylmethyl)benzimidazol-5-yl]sulfonyl-
2-pyridyl]oxy]propan-1-amine (CM-157) conjugated to a
fluorescent probe was developed in collaboration with Cisbio
Bioassays (Martínez-Pinilla et al., 2016).
Cannabinoid Isolation, Purification and
Analysis
Cannabidiol was purified from dried leaves and inflorescences
of the Cannabis variety SARA (CPVO file number: 20150098),
CBG from the variety AIDA (CPVO file number: 20160167)
following a previously described method (Nadal, 2016)
that provides compounds with >95% purity. An Agilent
liquid chromatography set-up (Model 1260, Pittsburgh,
PA, United States) consisting of a binary pump, a vacuum
degasser, a column oven, an autosampler and a diode array
detector (DAD) equipped with a 150 mm length × 2.1 mm
internal diameter, 2.7 µm pore size Poroshell 120 EC-C18
column was used for the quality control of the purified
cannabinoids. The analysis was performed using water and
acetonitrile both containing ammonium formate 50 mM as
mobile phases. Flow-rate was 0.2 mL/min and the injection
volume was 3 µL. Chromatographic peaks were recorded
at 210 nm. All determinations were carried out at 35◦C.
All samples were analyzed in duplicate. The results of each
cannabinoid purity, 96.04% for CBD and 99.9% for CBG,
were calculated as weight (%) versus a commercial standard
from THCpharm (CBD batch n◦ L01258-M-1.0; CBG batch n◦
L01260-M-1.0).
Radioligand Binding Assays
Cell Culture and Membrane Preparation
For radioligand binding experiments CHO cells, stably
transfected with cDNA for human CB1 or CB2 cannabinoid
receptors, were grown adherently and maintained in Ham’s
F12 containing 10% fetal bovine serum, penicillin (100 U/mL),
streptomycin (100 µg/mL) and geneticin (G418, 0.4 mg/mL)
at 37◦C in a humid atmosphere of 5% CO2. Membranes were
prepared from cells washed with PBS and scraped off plates in
ice-cold hypotonic buffer (5 mM Tris HCl, 2 mM EDTA, pH
7.4). The cell suspension was homogenized with a Polytron and
then centrifuged for 30 min at 40,000× g.
Saturation Binding Experiments
[3H]-CP-55940 saturation binding experiments (specific activity
169 Ci/mmol, Perkin Elmer) were performed incubating different
concentrations of the radioligand (0.03 – 10 nM) in binding
buffer (50 mM Tris-HCl, pH 7.4, 2.5 mM EDTA, 5 mM
MgCl2 for CB1R or 50 mM Tris-HCl, pH 7.4, 1 mM
EDTA, 5 mM MgCl2 for CB2R) using CHO membranes
expressing the human versions of CB1R or CB2R (10 µg
protein/sample) at 30◦C. Non-specific binding was determined
in the presence of 1 µM WIN-55,212-2. At the end of the
incubation period (90 min for CB1R or 60 min for CB2R)
bound and free radioactivity were separated in a cell harvester
(Brandel Instruments) by filtering the assay mixture through
Whatman GF/B glass fiber filters. The filter-bound radioactivity
was counted in a 2810 TR liquid scintillation counter (Perkin
Elmer).
[3H]-WIN-55,212-2 saturation binding experiments (specific
activity 48 Ci/mmol, Perkin Elmer) were performed incubating
different concentrations of the radioligand (0.5–100 nM for CB1R
or 0.2–40 nM for CB2R) in binding buffer (50 mM Tris-HCl,
pH 7.4, 1 mM EDTA, 5 mM MgCl2) with CB1R- or CB2R-
containing CHO cell membranes (10 µg protein/sample) at 30◦C.
Non-specific binding was determined in the presence of 1 µM
WIN-55,212-2. At the end of the incubation period (60 min)
bound and free radioactivity were separated in a cell harvester
(Brandel Instruments) by filtering the assay mixture through
Whatman GF/B glass fiber filters. The filter-bound radioactivity
was counted in a 2810 TR liquid scintillation counter (Perkin
Elmer).
Competition Binding Experiments
[3H]-CP-55940 competition binding experiments were
performed incubating 0.3 nM of radioligand and different
concentrations of the tested compounds with membranes
obtained from CHO cells expressing human CB1 or CB2
receptors (10 µg protein/sample) for 90 min (CB1R) or 60 min
(CB2R) at 30◦C. Non-specific binding was determined in the
presence of 1 µM WIN-55,212-2. Bound and free radioactivity
were separated by filtering the assay mixture as above indicated.
The filter bound radioactivity was counted using a Packard Tri
Carb 2810 TR scintillation counter (Perkin Elmer).
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Competition binding experiments were also performed
incubating 3 nM [3H]-WIN-55,212-2 and different
concentrations of the tested compounds with membranes
obtained from CHO cells transfected with human CB1 or
CB2 receptors (10 µg protein/sample) for 60 min at 30◦C.
Non-specific binding was determined in the presence of 1 µM
WIN-55,212-2. Bound and free radioactivity were separated by
filtering the assay mixture as above indicated. The filter bound
radioactivity was counted using a Packard Tri Carb 2810 TR
scintillation counter (Perkin Elmer).
Homogeneous Binding Assays in Living
Cells
Expression Vector
cDNAs for the human version of cannabinoid CB2R without
their stop codon were obtained by PCR and subcloned to SNAP-
containing vector (PSNAP; Cisbio Bioassays) using sense and
antisense primers harboring unique restriction sites for HindIII
and BamHI generating the SNAP tagged CB2R (CB2R-SNAP).
Cell Culture and Transfection
For HTRF assays, HEK-293T cells were used. HEK 293T
(HEK-293T) cells were grown in DMEM supplemented with
2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/mL
penicillin/streptomycin, and 5% (v/v) FBS [all supplements
were from Invitrogen, (Paisley, Scotland, United Kingdom)].
Cells were maintained at 37◦C in a humidified atmosphere
of 5% CO2 and were passaged, with enzyme-free cell
dissociation buffer (13151-014, Gibco R©, Thermo Fisher,
Waltham, MA, United States), when they were 80–90%
confluent, i.e., approximately twice a week. Cells were transiently
transfected with the PEI (Polyethylenimine, Sigma, St. Louis,
MO, United States) method as previously described (Medrano
et al., 2017; Navarro et al., 2018b). Experiments were carried out
in cells expressing SNAP-tagged CB2R in the presence or in the
absence of CB1R.
Labeling of Cells Expressing SNAP-Tagged CB2R
Cell culture medium was removed from the 25-cm2 flask and
100 nM SNAP-Lumi4-Tb, previously diluted in 3 mL of TLB
1X, was added to the flask and incubated for 1 h at 37◦C under
5% CO2 atmosphere in a cell incubator. Cells were then washed
four times with 2 mL of TLB 1X to remove the excess of SNAP-
Lumi4-Tb, detached with enzyme-free cell dissociation buffer,
centrifuged 5 min at 1,500 rpm and collected in 1 mL of TLB
1X. Tag-lite-based binding assays were performed 24 h after
transfection. Densities in the 2,500–3,000 cells/well range were
used to carry out binding assays in white opaque 384-well plates.
Non-radioactive Competition Binding Assays
For competition binding assays, the fluorophore-conjugated
CB2R ligand (labeled CM-157), unconjugated CM-157 and CBG
were diluted in TLB 1X. HEK-293T cells transiently expressing
Tb-labeled SNAP-CB2R with or without CB1R were incubated
with 20 nM fluorophore-conjugated CB2R ligand, in the presence
of increasing concentrations (0–10 µM range) of CBG or CM-
157. Plates contained 10 µL of labeled cells, and 5 µL of TLB 1X
or 5 µL of CBG or 5 µL CM-157 were added prior to the addition
of 5 µL of the fluorescent ligand. Plates were then incubated for
at least 2 h at room temperature before signal detection. Detailed
description of the HTRF assay is found in Martínez-Pinilla et al.
(2016).
Signal was detected using an EnVision microplate reader
(PerkinElmer, Waltham, MA, United States) equipped with a
FRET optic module allowing donor excitation at 337 nm and
signal collection at both 665 and 620 nm. A frequency of 10
flashes/well was selected for the xenon flash lamp excitation. The
signal was collected at both 665 and 620 nm using the following
time-resolved settings: delay, 150 µs; integration time, 500 µs.
HTRF R© ratios were obtained by dividing the acceptor (665 nm)
by the donor (620 nm) signals and multiplying by 10,000. The
10,000-multiplying factor is used solely for the purpose of easier
data handling.
Functional Assays
Cell Culture and Transient Transfection
HEK-293T cells were grown in DMEM medium (Gibco,
Paisley, Scotland, United Kingdom) supplemented with 2 mM
L-glutamine, 100 U/mL penicillin/streptomycin, MEM Non-
Essential Amino Acids Solution (1/100) and 5% (v/v) heat
inactivated Foetal Bovine Serum (FBS) (Invitrogen, Paisley,
Scotland, United Kingdom). Cells were maintained in a
humid atmosphere of 5% CO2 at 37◦C. Cells were transiently
transfected with the PEI (Polyethylenimine, Sigma, St. Louis,
MO, United States) method as previously described (Medrano
et al., 2017; Navarro et al., 2018b) and used for functional assays
48 h later (unless otherwise stated).
cAMP Determination
Signaling experiments have been performed as previously
described (Navarro et al., 2010, 2016, 2018b; Hinz et al.,
2018). Two hours before initiating the experiment, HEK-293T
cell-culture medium was replaced by serum-starved DMEM
medium. Then, cells were detached, resuspended in growing
medium containing 50 µM zardaverine and placed in 384-well
microplates (2,500 cells/well). Cells were pretreated (15 min)
with CBG -or vehicle- and stimulated with agonists (15 min)
before adding 0.5 µM forskolin or vehicle. Readings were
performed after 15 min incubation at 25◦C. HTRF energy transfer
measures were performed using the Lance Ultra cAMP kit
(PerkinElmer, Waltham, MA, United States). Fluorescence at
665 nm was analyzed in a PHERAstar Flagship microplate reader
equipped with an HTRF optical module (BMG Lab Technologies,
Offenburg, Germany).
ERK Phosphorylation Assays
To determine ERK1/2 phosphorylation, 50,000 HEK-293T
cells/well were plated in transparent Deltalab 96-well microplates
and kept at the incubator for 24 h. 2 to 4 h before the experiment,
the medium was substituted by serum-starved DMEM medium.
Then, cells were pre-treated at 25◦C for 10 min with vehicle
or CBG in serum-starved DMEM medium and stimulated for
an additional 7 min with the specific agonists. Cells were
then washed twice with cold PBS before addition of lysis
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buffer (20 min treatment). 10 µL of each supernatant were
placed in white ProxiPlate 384-well microplates and ERK 1/2
phosphorylation was determined using AlphaScreen R©SureFire R©
kit (Perkin Elmer) following the instructions of the supplier
and using an EnSpire R© Multimode Plate Reader (PerkinElmer,
Waltham, MA, United States).
Dynamic Mass Redistribution Assays (DMR)
Cell mass redistribution induced upon receptor activation was
detected by illuminating the underside of a biosensor with
polychromatic light and measuring the changes in the wavelength
of the reflected monochromatic light. The magnitude of this
wavelength shift (in picometers) is directly proportional to the
amount of DMR. HEK-293T cells were seeded in 384-well sensor
microplates to obtain 70–80% confluent monolayers constituted
by approximately 10,000 cells per well. Previous to the assay, cells
were washed twice with assay buffer (HBSS with 20 mM HEPES,
pH 7.15) and incubated for 2 h with assay-buffer containing
0.1% DMSO (24◦C, 30 µL/well). Hereafter, the sensor plate was
scanned and a baseline optical signature was recorded for 10 min
before adding 10 µL of CBG for 30 min followed by the addition
of 10 µL of specific agonists; all test compounds were dissolved in
assay buffer. The cell signaling signature was determined using an
EnSpire R© Multimode Plate Reader (PerkinElmer, Waltham, MA,
United States) by a label-free technology. Then, DMR responses
were monitored for at least 5,000 s. Results were analyzed using
EnSpire Workstation Software v 4.10.
β-Arrestin 2 Recruitment
Arrestin recruitment was determined as previously described
(Medrano et al., 2017; Navarro et al., 2018b). Briefly, BRET
experiments were performed in HEK-293T cells 48 h after
transfection with the cDNA corresponding to the CB2R-YFP
or CB1R-YFP and 1 µg cDNA corresponding to β-arrestin
2-Rluc. Cells (20 µg protein) were distributed in 96-well
microplates (Corning 3600, white plates with white bottom)
and were incubated with CBG for 15 min and stimulated
with the agonist for 10 min prior the addition of 5 µM
coelenterazine H (Molecular Probes, Eugene, OR, United States).
After 1 min of adding coelenterazine H, BRET between
β-arrestin 2-Rluc and receptor-YFP was determined and
quantified. The readings were collected using a Mithras LB
940 (Berthold Technologies, Bad Wildbad, Germany) that
allows the integration of the signals detected in the short-
wavelength filter at 485 nm and the long-wavelength filter at
530 nm. To quantify protein-RLuc expression luminescence
readings were also performed 10 min of adding 5 µM
coelenterazine H.
Data Handling and Statistical Analysis
Affinity values (Ki) were calculated from the IC50 obtained in
competition radioligand binding assays according to the Cheng
and Prusoff equation: K i = IC50/(1 + [C]/KD), where [C] is the
free concentration of the radioligand and KD its dissociation
constant (Cheng, 2001).
Data from homogeneous binding assays were analyzed using
Prism 6 (GraphPad Software, Inc., San Diego, CA, United States).
K i values were determined according to the Cheng and Prusoff
equation with KD = 21 nM for CM-157 (Cheng, 2001). Signal-to-
background (S/B ratio) calculations were performed by dividing
the mean of the maximum value (µmax) by that of the minimum
value (µmin) obtained from the sigmoid fits.
The data are shown as the mean ± SEM. Statistical analysis
was performed with SPSS 18.0 software. The test of Kolmogorov–
Smirnov with the correction of Lilliefors was used to evaluate
normal distribution and the test of Levene to evaluate the
homogeneity of variance. Significance was analyzed by one-
way ANOVA, followed by Bonferroni’s multiple comparison





Membranes Expressing CB1R or CB2R
The effect of CBG on radioligand binding to CB1R or CB2R
was first tested using the classical radioligand-binding assay in
membranes isolated from CHO cells expressing human CB1R or
CB2R and incubated with radioligands: [3H]-CP-55940 or [3H]-
WIN-55,212-2. Data obtained from binding isotherms using
increasing [3H]-CP-55940 or [3H]-WIN-55,212-2 concentrations
lead to a monophasic saturation curve. Saturation curves,
receptor density (Bmax values) and affinity (KD values) are shown
in Figures 1A–D. The affinity of the two radioligands was in the
nanomolar range for both CB1R and CB2R. KD for [3H]-CP-
55940 to CB1R and CB2R was similar with values around 0.3 nM.
KD values for WIN-55,212-2 were 9.4 and 3.2 nM for CB1R and
CB2R, respectively (Figures 1C,D). Overall the results agree with
previously reported data (McPartland et al., 2007; Merighi et al.,
2010).
Competition binding assays of WIN-55,212-2 showed similar
K i values using the two radioligands to CB1R and CB2R and
agreed with the KD values for [3H]-WIN-55,212-2 binding
(Table 1 and Figures 1E,F). Table 1 reports the affinity values
of CBG. K i values of CBG obtained using [3H]-CP-55940 as
radioligand were in the low micromolar range in both CB1R
and CB2R. The affinity value of CBG obtained using [3H]-
WIN-55,212-2 for CB2R was 2.7 µM, about twofold higher than
that obtained using [3H]-CP-55940. Using [3H]-WIN-55,212-
2 in competition binding experiments on CB1R, CBG was not
able to displace the radioligand (Figures 2A,B). In summary,
CBG displayed K i values in the low micromolar range when
competing for the binding to the CB2R. Surprisingly, significant
competition in the binding to the CB1R was only observed when
using [3H]-CP-55940 as radioligand.
CBG Binds to the Orthosteric Site of
Cannabinoid CB2R at Nanomolar
Concentrations
Competition experiments were performed using 20 nM of a
fluorophore-conjugated selective CB2R agonist (CM-157) and
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FIGURE 1 | Radioligand binding assays to CB1R and CB2R. (A–D) Saturation curves of either [3H]-CP-55940 or [3H]-WIN-55,212-2 binding on membranes from
CHO cells stably expressing human CB1R (A,C) or CB2R (B,D). (E,F) Competition curves for WIN-55,212-2 in radioligand-based assays using either [3H]-CP-55940
(E) or [3H]-WIN-55,212-2 (F) binding on membranes from CHO cells stably expressing human CB1R or CB2R. Data are expressed as the mean ± SEM of five
independent experiments performed in duplicate. KD (obtained from saturation isotherms) are shown in Table 1.
a homogeneous non-radioactive method performed in living
cells expressing SNAP-CB2R (details in Martínez-Pinilla et al.,
2016; Figure 2C). Unfortunately, the equivalent fluorophore-
conjugated selective CB1R ligand is not available to perform
HTRF assays in SNAP-CB1R-expressing living cells. Competition
assays were performed in HEK-293T cells expressing Lumi4-
Tb-labeled CB2R fused to the SNAP protein and incubated
with a fixed amount of the fluorophore-conjugated agonist and
different CBG concentrations. As observed in Figure 2, both
the unlabelled selective agonist (CM-157) and CBG decreased
the binding to SNAP-CB2R in monophasic fashion and with
K i values in the nanomolar range (16 nM for CM-157 and of
152 nM for CBG; Figures 2D,E). The K i obtained for CM-157
matches with previously reported dissociation constant KD
values (Martínez-Pinilla et al., 2016). These results indicate that
CBG can significantly bind to the orthosteric site of cannabinoid
CB2R at nanomolar concentrations.
Similar experiments were carried out in HEK-293T cells
expressing SNAP-CB2R fusion protein and a similar amount of
CB1R, i.e., in cells that express CB2R in a CB1–CB2 receptor
heteromer context. In the presence of cannabinoid CB1R the K i
for CM-157 was 19 nM (Figure 2F) and K i for CBG was reduced
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TABLE 1 | Affinity values of CB compounds obtained from radioligand binding assays.
[3H]-CP-55940 competition binding experiments [3H]-WIN-55,212-2 competition binding experiments
CB1 – KD (nM) CB2 – KD (nM) CB1 – KD (nM) CB2 – KD (nM)
0.29 ± 0.02 0.32 ± 0.02 9.43 ± 0.83 3.16 ± 0.24
CB1 – Ki (nM) CB2 – Ki (nM) CB1 – Ki (nM) CB2 – Ki (nM)
WIN-55,212-2 8.08 ± 0.65 3.22 ± 0.31 9.86 ± 0.84 3.48 ± 0.27
CBG 1,045 ± 74 1,225 ± 85 >30,000 2,656 ± 130
CBD 1,690 ± 110 1,714 ± 70 >30,000 4,019 ± 342
KD values were obtained from saturation isotherms and Ki from data in competition assays using the indicated radiolabelled compounds ([3H]-CP-55940 or [3H]-WIN-
55,212-2).
(56 nM, Figure 2G). These results indicate that in cells expressing
both cannabinoid receptors, CB1 and CB2, CBG shows higher
affinity for cannabinoid CB2R.
CBG Effects on Cannabinoid
Receptor-Agonist-Induced Effects
Previous reports Gauson et al. (2007), Cascio et al. (2010) suggest
that CBG may be a partial agonist of cannabinoid receptors.
To investigate this possibility, HEK-293T cells expressing CB1R
or CB2R were treated with increasing concentrations of CBG
(1 nM to 10 µM) and cAMP, MAPK, β-arrestin recruitment and
dynamic mass cell redistribution (DMR) assays were developed.
Interestingly, it was observed that in cells expressing CB1R
(Figure 3, blue curves), CBG induced a small decrease in
forskolin induced cAMP levels and a small increase in β-arrestin
recruitment (Figures 3A,C), while having no significant action
on MAPK phosphorylation assay (Figure 3B). Consequently,
CBG in label-free assays induced a slight effect in the DMR
signal (Figure 3D) that is consistent with a G protein-
dependent action on cAMP levels; label-free signal is based
on optical detection of DMR following receptor activation
and mainly reflects G-protein-coupling (Kebig et al., 2009;
Schröder et al., 2009; Hamamoto et al., 2015). On the other
hand, in HEK-293T cells expressing CB2R (Figure 3, red
curves), the action on forskolin-induced cAMP levels and
on the DMR signal was small and similar to that exerted
in CB1R-expressing cells (Figure 3A). On the contrary, the
activation of the MAP kinase pathway was notable (Figure 3B).
Also noteworthy was the CBG-induced β-arrestin recruitment
(Figure 3C). Taken together these data suggest that CBG is
a poor agonist of CB1R, whereas it acts as a partial agonist
in some of the signaling pathways analyzed in cells expressing
CB2R.
To further examine the CBG effect over CB1R, HEK-293T
cells expressing CB1R were treated with the endocannabinoid
agonist, AEA, or with ACEA in the presence or in the absence
of 100 nM or 1 µM CBG. In forskolin-induced cAMP assays
we found that 100 nM or 1 µM CBG pretreatment induced
a significant decrease in both, AEA and ACEA induced effects
(Figure 4A). In contrast, CBG (100 nM or 1 µM) was
unable to modify the agonist-induced MAPK phosphorylation
and β-arrestin recruitment (Figures 4B,C). In label-free DMR
assays the results were similar to those obtained in cAMP
determination assays, i.e., CBG reduced the effect of the agonists
(Figure 4D).
Cannabigerol (100 nM or 1 µM) was also tested in HEK-293T
cells expressing CB2R and using AEA and a receptor selective
agonist, JWH133. Pretreatment with CBG reduced the effects of
AEA and JWH133 in experiments of forskolin-induced cAMP
levels, ERK1/2 phosphorylation and in label-free DMR read-
outs (Figure 4). In contrast, CBG did not affect the recruitment
of β-arrestin induced by agonists (Figure 4G). This last result
may be due to the low sensitivity of the assay as β-arrestin
recruitment BRET signal was virtually negligible. Energy transfer
techniques completely depend on the correct orientation of the
fusion proteins and the reduced signal may be due to poor
recruitment of β-arrestin and/or to a high distance between
BRET donor/acceptor in the putative β-arrestin-Rluc/CB2R-YFP
complex. Thus, CBG in cells activated by endocannabinoids
or by selective agonists behaves as a partial agonist of the
CB2R.
CBG Effect in HEK-293T Cells
Expressing CB1R and CB2R
Experiments were finally performed in cells co-expressing the
two cannabinoid receptors, which are able to form heteromeric
complexes. A CB1–CB2 receptor heteromer print consists of
a negative cross-talk observed in Akt phosphorylation and
neurite outgrowth; i.e., activation of one receptor reduces the
signaling originated upon partner receptor activation (Callén
et al., 2012). To characterize the CBG effect, experiments were
performed in HEK-293T cells expressing the two cannabinoid
receptors. Dose-effect curves were provided for cAMP level
and ERK1/2 phosphorylation determination, and for label-free
DMR signal and β-arresting recruitment. Interestingly, the
effect on cAMP level determination and DMR assays was
additive (Figure 5), i.e., the presence of CBG blunted the
negative cross-talk in these signaling pathways. However,
the negative cross-talk was still evident in both ERK1/2
phosphorylation and β-arrestin recruitment experiments
(Figures 5B,C).
Finally, the effect of 100 nM CBG (100 nM) on AEA, ACEA
and/or JWH133 actions was investigated in cells co-expressing
CB1R and CB2R. CBG pretreatment led to significant effects,
always reducing the effect of the agonists, in cAMP-related assays
(Figure 5E). However, the effect in the other assay types was
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FIGURE 2 | Competition by CBG of agonist binding to CB1R and/or CB2R. (A,B) Competition curves for CBG in radioligand-based assays using either
[3H]-CP-55940 (A) or [3H]-WIN-55,212-2 (B) binding on membranes from CHO cells stably expressing human CB1R or CB2R. (C) Scheme of the HTRF-based
competitive binding assay. The GPCR of interest with the SNAP-tagged enzyme fused to its N-terminal domain is expressed at the cell surface. SNAP is a
commercially available tag consisting of circa 180 amino acids, that can be labeled with fluorophores or other probes in a covalent fashion. The GPCR–SNAP-tagged
cells are subsequently labeled with a Tb-containing probe (SNAP-Lumi4-Tb) through a covalent bond between the Tb and the reactive side of the SNAP enzyme.
The Tb acts as FRET donor of an acceptor covalently linked to a selective CB2 receptor ligand. Thus, upon binding of a fluorophore-conjugated ligand (FRET
acceptor) on the donor-labeled SNAP-tagged/GPCR fusion protein, an HTRF signal from the sensitized acceptor can be detected since the energy transfer can
occur only when the donor and the acceptor are in close proximity. In competition binding assays using CM-157, the unlabelled specific ligand competes for receptor
binding site with the fluorophore-conjugated ligand, leading to a decrease in the HTRF signal detected. (D–G) HEK-293T were transiently transfected with 1 µg
cDNA for SNAP-CB2R in the absence (D,E) or presence of 0.5 µg cDNA for CB1R (F,G). Competition curves of specific binding of 20 nM fluorophore-conjugated
CM-157 using CM-157 (0–10 µM) (D,F) or of CBG (0–10 µM) (E,G) as competitors are shown. Data represent the mean ± SEM of five experiments in triplicates.
Frontiers in Pharmacology | www.frontiersin.org 8 June 2018 | Volume 9 | Article 632
fphar-09-00632 June 19, 2018 Time: 19:17 # 9
Navarro et al. Cannabigerol Action at Cannabinoid Receptors
FIGURE 3 | Cannabigerol action in cells expressing CB1R or CB2R. HEK-293T cells were transfected with 0.75 µg cDNA for CB1R (red line) or 1 µg cDNA for CB2R
(blue line). Dose–effect curves for cAMP production are expressed as % of levels obtained by 0.5 µM forskolin treatment (A). Dose-effect curves for ERK1/2
phosphorylation are expressed as % respect to basal levels (B). Dose-effect curves for β-arrestin recruitment (C) and label-free (D) assays are expressed,
respectively, in mBRET units and pm. In β-arrestin-2 recruitment assays cells were transfected with 1 µg cDNA for β-arrestin-Rluc and either 0.75 µg cDNA for
CB1R-YFP or 1 µg cDNA for CB2R-YFP. Data are the mean ± SEM of a representative experiment in triplicates (n = 6).
negligible except for the negative modulation of the ACEA effect
on ERK1/2 phosphorylation and DMR, and of the AEA effect on
DMR read-outs (Figures 5F–H). Therefore, CBG either blunted
the cAMP-dependent signaling or did not significantly alter
the negative cross-talk when other CB1/CB2-mediated signaling
read-outs were determined (see Figures 5B,C). It should be noted
that cross-talk at the intracellular signaling level, cannot be ruled
out to partly explain some of the findings (Bayewitch et al., 1995;
Wartmann et al., 1995; Mcguinness et al., 2009; Peters and Scott,
2009; Van Der Lee et al., 2009).
DISCUSSION
The aim of this paper was to comparatively address CBG
pharmacology and effects on CB1 and CB2 receptors, and on
CB1–CB2 heteroreceptor complexes. The binding experiments
using radiolabelled- and non-radiolabelled-based approaches
have provided relevant results. The results on CB2R are clear
an indicate that CBG acts as a competitive partial agonist
ligand. There is, however, an interesting observation as the
K i values for competing both [3H]-CP-55940 and [3H]-WIN-
55,212-2 are in the low micromolar range (Table 1), whereas
displaying a value of 152 nM in HTRF-based assays. As pointed
out in previous reports, the conditions of the approach using a
fluorescent-conjugated CM-157 allows identification of different
states of the receptor. Irrespective of the molecular mechanism,
the marked differences in affinity constants suggest different
ways to accommodate the ligand within the orthosteric center.
To our knowledge this is the first report performed in parallel
binding assays using three different ligands that reportedly
bind to the orthosteric center of the CB2R ([3H]-CP-55940,
[3H]-WIN-55,212-2 and fluorescence-conjugated-CM-157). In
summary, the most reasonable assumption is that CBG binds
to the orthosteric center of CB2R but with marked differences
in affinity depending on the assay. It should be noted that
differences in affinity may result from the fact that HTRF binding
is performed in living cells whereas radioligand binding assays
are performed in isolated membranes. The already existing
data concerning CBG affinity for CB1 and CB2 receptors, all
performed using [3H]-CP-55940 also indicate that the affinity
may vary depending on the context of the receptor, by inter alia
the constraints of the membrane, heteromerization or interaction
with G-proteins. Comparing our results with similar data using
[3H]-CP-55940, the affinity is higher for receptors expressed in
HEK-293 cells or in brain membranes (Gauson et al., 2007;
Pertwee, 2008; Pollastro et al., 2011) that in receptors expressed
in CHO cells (Table 1). In competition assays of radioligand
binding to CB1R or to CB2R, affinity for CBG is similar to
that previously published (Gauson et al., 2007; Pertwee, 2008),
except in the case of Sf9 cells (K i: 897 and 153 nM for,
respectively, CB1R and CB2R). This piece of data would indicate
conformational changes induced by third molecules that affect
the binding of the radioligand and/or of CBG. In fact, Sf9 are
insect cells that do not express the cognate Gi protein and,
therefore, Gαi3β1γ2 was heterologously expressed to perform the
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FIGURE 4 | Effect of CBG on the action of CB1R and CB2R agonists. (A–D) HEK-293T cells were transfected with 0.75 µg cDNA for CB1R and treated with
100 nM AEA or a selective CB1R ligand (100 nM ACEA) in the absence (black bars) or presence of 100 nM (white bars) or 1 µM (gray bars) CBG. (E–H) HEK-293T
cells were transfected with 1 µg cDNA for CB2R and treated with 100 nM AEA or a selective CB2R ligand (100 nM JWH133) in the absence (black bars) or presence
of 100 nM (white bars) or 1 µM (gray bars) CBG. cAMP production (A,E) is expressed as % of levels obtained by 0.5 µM forskolin. ERK1/2 phosphorylation data are
expressed as % respect to basal levels (B,F). In β-arrestin-2 recruitment assays cells were transfected with 1 µg cDNA for β-arrestin-Rluc and either 0.75 µg cDNA
for CB1R-YFP or 1 µg cDNA for CB2R-YFP. Data for β-arrestin recruitment (C,G) and label-free (D,H) assays are expressed, respectively, in mBRET units and pm.
Data represent the mean ± SEM of six different experiments performed with six replicates. One-way ANOVA and Bonferroni’s multiple comparison post hoc test
were used for statistical analysis (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; versus treatment with AEA, ACEA, or JWH133 alone).
binding assays that led to different affinities for CBG (897 and
153 nM for, respectively, CB1R and CB2R) (Rosenthaler et al.,
2014).
The results from binding to the CB1R are not very robust and
more difficult to interpret. Unfortunately, there are no ligands
available to perform HTRF binding to SNAP-CB1R-expressing
living cells, whereas the data from competition assays using [3H]-
CP-55940 or [3H]-WIN-55,212-2 were contradictory. On the one
hand, the K i for binding to the CB1R using [3H]-CP-55940 was
in the low micromolar range, as it occurred with data from
radioligand binding to the CB2R. However, CBG was unable to
compete [3H]-WIN-55,212-2 binding to the CB1R. Taking into
account that recognition sites for CP-55940 and WIN-55,212-2
are not identical in the CB1R, one possibility is that CBG binds
to the orthosteric center but displaying different equilibrium
binding parameters depending on the radioligand. It was early
observed that Lys192 in the CB1R third transmembrane domain
(TM3) was crucial for binding of CP-55940 and AEA but not
for WIN-55,212-2 (Bonner et al., 1996; Chin et al., 1998). Later,
in silico models pointed to an hydrophobic pocket for CP-55940
binding that involved residues in different transmembrane
domains (not only in TM3) and in the second extracellular loop
(Shim et al., 2003). Those models showed that WIN-55,212-2
not only binds to the hydrophobic pocket described for CP-
55940 but to another hydrophobic region involving residues
in TM2 and TM3 (Shim and Howlett, 2006). The structure
of CBG is more similar to CP-55940 than to WIN-55,212,2,
bearing an OH in the A ring that may interact with the TM3
Lys192 residue. In brief, CBG binds to the orthosteric center
of CB1R as indicated by the fact that CBG affects CP-55940
binding without affecting the binding of [3H]-WIN-55,212-2.
In other words, CBG was able to distinguish between two
subregions of the CB1R orthosteric center. We therefore suggest
that pharmacological studies concerning the CB1R should be
run in parallel using radiolabelled CP-55940 and WIN-55,212-
2. Interestingly CP-55940 and WIN-55,212-2 are able to fix the
CB1R in two different conformations (Georgieva et al., 2008)
and, therefore, CBG would affect more the conformation and
signaling arising from occupation of the CP-55940 binding site.
Other possibilities cannot be ruled out and, in this respect,
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FIGURE 5 | Effect of CBG in cells expressing CB1 and CB2 receptors. (A–D) Effect of CBG in HEK-293T cells transfected with 0.75 µg cDNA for CB1R and 1 µg
cDNA for CB2R (A,B,D) or 1 µg cDNA for β-arrestin-Rluc, 0.75 µg cDNA for CB1R and 1 µg cDNA for CB2R-YFP (C). Dose–effect curves for cAMP production are
expressed as % of levels obtained by 0.5 µM forskolin treatment (A). Dose-effect curves for ERK1/2 phosphorylation are expressed as % respect of basal levels (B).
Dose-effect curves for β-arrestin recruitment (C) and label-free (D) assays are expressed, respectively, in mBRET units and pm. Dotted lines (red and blue) are the
same than those shown in Figure 3 and serve as a reference for differential effects in cells coexpressing both receptors. Data are the mean ± SEM of a
representative experiment in triplicates (n = 6). (E–H) HEK-293T cells transfected with 0.75 µg cDNA for CB1R and 1 µg cDNA for CB2R (E,F,H) or 1 µg cDNA for
β-arrestin-Rluc, 0.75 µg cDNA for CB1R and 1 µg cDNA for CB2R-YFP (G) were treated with 100 nM AEA or a selective CB2R ligand (100 nM JWH133) in the
absence (black bars) or presence (white bars) of 100 nM CBG. cAMP production (E) is expressed as % of levels obtained by 0.5 µM forskolin. ERK1/2
phosphorylation data are expressed as % respect of basal levels (F). Data for β-arrestin recruitment (G) and label-free (H) assays are expressed, respectively, in
mBRET units and pm. Data represent the mean ± SEM of six different experiments performed with three replicates. One-way ANOVA and Bonferroni’s multiple
comparison post hoc test were used for statistical analysis (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; versus treatment with AEA, ACEA, or JWH133 alone).
we assayed CBD in competition assays and obtained similar
results than those obtained using CBG (Table 1). Accordingly,
CBG could act on CB1R (but not on CB2R) as non-competitive
(allosteric) modulator, as described for CBD (Laprairie et al.,
2015).
When one compound binds to the orthosteric center and
affects several signaling pathways with different potency as in the
case of CBG in cells expressing CB1R, the phenomenon is known
as functional selectivity or biased agonism. In cells expressing
CB1R, CBG effect is skewed toward the Gi-mediated signaling
pathway. This is in agreement with our finding of significant
effect in label-free assays; often DMR signals correlate with effect
on cAMP levels in the case of receptors coupled to Gi or Gs
proteins (Grundmann and Kostenis, 2015a,b; Hamamoto et al.,
2015). It is, however, intriguing that CBG was unable to displace
the binding of [3H]-WIN-55,212-2 to the CB1R. Therefore, an
action of CBG on a particular state of the receptor, which,
in the case of CB2R may be disclosed by HTRF binding in
living cells (Martínez-Pinilla et al., 2016), cannot be ruled out.
Taking together all results, an allosteric action of CBG on the
CB1R would not explain why it is able to engage Gi –mediating
signaling. Another possibility, which was suggested for AM630,
a previously considered CB2R antagonist (Bolognini et al.,
2012), is that CBG is a protean agonist displaying biased
agonism.
Data from CB2R-mediated functional assays were easier to
interpret. First of all, the efficacy was lower compared to selective
synthetic agonists and endocannabinoids. Also, CBG led to
biased agonism as the effect on cAMP levels was small while
being quite marked in ERK phosphorylation and β-arrestin
recruitment. Therefore, CBG acted as a partial agonist and, as
such, it was able to reduce the effects of other cannabinoid
agonists. At 1 µM the effect of CBG on receptor activation by
other agonists was similar to that exerted by 100 nM (Figure 4)
thus suggesting that the effective affinity in living cells is that
obtained in HTRF non-radioactive-based assays.
Due to the complex pharmacology of cannabinoids this
research was undertaken to investigate whether CBG could
be exerting a differential action on the CB1–CB2 receptor
heteromers. Previous data have shown that the interplay between
the two receptors in an heteromeric context is also complex.
Whereas Callén et al. (2012) showed a negative cross-talk in
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a heterologous expression system, the allosteric interaction in
the CB1–CB2 heteroreceptor complex is synergistic in primary
cultures of activated microglia activated with LPS and interferon
gamma and in primary cultures of microglia from a transgenic
model of Alzheimer’s disease (Navarro et al., 2018a). Dose-
effect experiments here undertaken in the HEK-293T-based
heterologous expression system showed that CBG treatment in
the absence of any other agonist, led to additive/synergistic
effects on cAMP and label-free read-outs. In contrast, in
ERK phosphorylation and β-arrestin recruitment, we found the
negative cross-talk already described for this heteromer when
full agonists are used to activate the receptors (Callén et al.,
2012). These results suggest that partial agonism on the CB2R
is regulated by the presence of CB1R; however, more complex
alternative scenarios cannot be ruled out as CBG may act on the
orthosteric site of the CB2R protomer and as protean agonist of
the CB1R protomer. In cells expressing the two receptors, the
overall effect of 100 nM CBG on agonist-induced activation is
more consistent with acting on CB2R than on CB1R. In fact, the
results in co-expressing cells, which likely express heteromers,
are similar to those encountered in CB2R-expressing cells. In
summary, CBG significantly modulates CB2R- or CB1R/CB2R-
mediated endocannabinoid action, while the effects are weak in
CB1R-expressing cells. Our findings demonstrating the action of
CBG on the cannabinoid receptors are in complete agreement
and may explain the in vitro results, reporting the protection of
macrophages against oxidative stress (Giacoppo et al., 2017), and
the beneficial in vivo effects in a model of inflammatory bowel
disease (Borrelli et al., 2013). In the first of these two studies
CBG-mediated protection is blocked by AM630, a selective
CB2R ligand, whereas the CB1R antagonist, SR141716A, had
no effect on CBG action (Giacoppo et al., 2017). The second
study reported that CBG may both reduce the histological and
molecular changes of experimental colitis and nitrite release
from macrophages after LPS stimulation; again these effects were
seemingly mediated by CB2R (Borrelli et al., 2013). These results
can be explained by our findings; CBG acting as a partial agonist
and exerting actions via CB2R in macrophages (Giacoppo et al.,
2017) or “antagonizing” the effects of endogenous or synthetic
cannabinoids, as in LPS-stimulated macrophages (Borrelli et al.,
2013). In conclusion, the results presented in this study reveal
that the non-psychotropic phytocannabinoid, CBG, may exert
beneficial actions with therapeutic potential via cannabinoid
receptors.
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